Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), has reportedly raised $42 million via a Series A financing round. The funding round was led by Lanchi Ventures, with additional contributions from YuanBio Venture Capital, Legend Capital, and Xiamen C&D Emerging Industry Equity Investment, along with returning investors Gaorong Capital and Med-Fine Capital.
Funding Allocation and Pipeline Advancement
The proceeds from the financing will be utilized to accelerate Allink Biotherapeutics’ global layout, including the advancement of Phase I clinical studies for its core pipelines, ALK201 and ALK202, in Australia, the United States, and China. The company plans to expand its cancer and immune disease pipelines and optimize its in-house BsAb and ADC technology platforms.
Expanding Pipeline and Technology Platforms
By investing in the development of its BsAb and ADC technology platforms, Allink Biotherapeutics aims to strengthen its position in the biotech industry and enhance its capabilities to bring innovative treatments to market. The expansion of its cancer and immune disease pipelines reflects the company’s commitment to addressing unmet medical needs and improving patient outcomes.-Fineline Info & Tech
Leave a Reply